Search Results for "BIAL Pharmaceuticals"

00:14 EDT 24th March 2017 | BioPortfolio

Matching Channels


Located in the north-east corner of the USA, Massachusetts, has the third highest GDP of any state in America and is also a hotspot for the biotechnology industry. In addition to the globally renown...

The Top 100 Drugs

The pharmaceutical industry is massive, both in range of products and in financial values. These are the top 200 drugs (ranked in descending order according to total sales in 20010, $), and the co...

Datamonitor - aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapidly evolving marketplace

The Datamonitor Group aims to help its clients operating in the pharmaceuticals, healthcare and biotechnology fields, offering world-leading products and services to meet the challenges of this rapi...


Surrounded by the Great Lakes in the north east of the US, Michigan hosts many high profile biotechnology companies and has become an industry hotbed. In 1993 MichBio was formed, as an industry tr...


Covidien is the 9th largest global medical device company with annual sales in 2010 of almost $8 billion. Covidien was originally Tyco Healthcare, until June 2007, and has seen year-on-year growth s...

Matching News

BIAL signs mega-million-$ deal for Parkinson’s drug in North America

USA-based Neurocrine Biosciences and Portuguese pharmaceutical firm BIAL have entered into an exclusive…

UK launch for Bial’s Parkinson’s drug

Patients with Parkinson's disease in the UK can now potentially access a new option to treat motor fluctuations with the launch of Bial's Ongentys across the country.

Portugal’s Bial launches Ongentys for Parkinson´s disease in UK

Bial says that its Ongentys (opicapone) has now been launched in the UK for the treatment of adult Parkinson´s…

BIAL sells allergic immunotherapy business to Roxall

Portuguese pharmaceutical firm BIAL has agreed to sell its allergic immunotherapy business to German…

Neurocrine gets rights to Bial-Portela's PD drug

Bial-Portela & Ca. S.A. (S. Mamede do Coronado, Portugal) granted Neurocrine Biosciences Inc. (NASDAQ:NBIX) exclusive, North American rights to Parkinson's disease drug Ongentys opicapone (

Neurocrine Nabs BIAL's PD Therapy Opicapone for North America

Neurocrine Biosciences is paying Portuguese firm BIAL $30 million up front for exclusive rights to develop the latter’s EU-approved Parkinson’s disease drug, ONGENTYS® (opicapone), in North A...

Bial Sells Allergic Immunotherapy Business

  Life Sciences Jobs   ...

Neurocrine Biosciences Nabs North American Rights to Bial's ONGENTYS

  Life Sciences Jobs   ...

Matching PubMed Articles

Progress Confirmed for Pharmaceuticals in 2016.


About fundamentals and sermonizers. Author's response to the letter on the article "The BIAL/Biotrial case of death of a human volunteer in the first-in-human study of BIA 10-2474: Are we missing the fundamentals?"

Temporal and spatial behavior of pharmaceuticals in Narragansett Bay, Rhode Island, United States.

The behavior and fate of pharmaceutical ingredients in coastal marine ecosystems is not well understood. To address this, the spatial and temporal distribution of 15 high volume pharmaceuticals were m...

Announcing the 2016 Pharmaceuticals Travel Award for Young Investigators.

For the first time in its short history, our journal is able, this year, to support a young researcher in the field of medicinal chemistry by offering a travel grant of 800 CHF.[...].

Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka.

Antibiotics and antidepressants are among the most successful drugs used for human therapy. Their concentration in influent on WWTP is relative high and there can be removed by biodegradation or sorpt...

Search Whole site using Google

Quick Search
Advertisement Advertisement